Celgene Corp. buy tamam
Start price
19.03.17
/
50%
€113.26
Target price
12.11.18
€127.22
Performance (%)
-41.19%
End price
12.11.18
€66.61
Summary
This prediction ended on 12.11.18 with a price of €66.61. The BUY prediction by tamam for Celgene Corp. performed very badly with a performance of -41.19%. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Celgene Corp. | - | - | - | - |
| iShares Core DAX® | -0.046% | 5.960% | 7.403% | 65.851% |
| iShares Nasdaq 100 | 0.922% | 3.693% | 28.138% | 93.298% |
| iShares Nikkei 225® | 3.014% | 6.638% | 48.886% | 89.079% |
| iShares S&P 500 | -0.359% | 2.747% | 22.530% | 71.942% |
Comments by tamam for this prediction
In the thread Celgene Corp. diskutieren
Celgene is a true "buy & hold" name in the biotech sector
tamam stimmt am 19.03.2017 der Outperform-Einschätzung der institutionellen Analysten mit dem Kursziel 141.04$ zu.
(Vom Mitglied beendet)